Insights

What sent the Race Oncology (ASX:RAC) share price rocketing 20% today?

The Race Oncology share price fired up 15% higher today with nothing new reported. We check out the latest quarterly update for some details.
The post What sent the Race Oncology (ASX:RAC) share price rocketing 20% today? appeared first on The Motley Fool Australia. –

Investor riding a rocket blasting off over a share price chart

The Race Oncology Ltd (ASX: RAC) share price rocketed 20.98% today, closing the day at $2.48 per share.

Race Oncology Ltd (RAC) is an Australian pharmaceutical company with developments in the cancer field. The company produces a chemotherapy drug called Bisantrene, which has been the subject of more than 40 phase II clinical studies.

Today’s gains cap off a big week for the Race Oncology share price, which has boosted more than 45% in the past 5 days.

While there was no news out of Race Oncology today, its quarterly report was released on 27 January 2021. We take a closer look at the company’s recent performance. 

A summary of the Race Oncology financials

In its most recent quarterly report for the period ended 31 December 2020, Race Oncology reported cash and equivalents of $5.58 million, compared with $5.66 million at 30 September 2020. 

Net outflows were supported by a $262,000 cash injection received from conversion of options and receipt of the $387,000 R&D tax rebate. 

Operating activities totalled $728,000, a decrease of $115,000 from the prior quarter.

Race Oncology currently has a market capitalisation of $275.7 million with 129.5 million shares outstanding.

Race Oncology announces new ‘three pillar’ strategic plan

Race Oncology also used the quarterly update to announce the company’s new ‘three pillar’ strategic plan.

The concept behind the plan is to maximise the potential down-streaming from activities related to the company’s Bisantrene treatment. This includes license applications or corporate sales to scaled pharmaceutical companies.

The company believes the new strategy will “significantly expand” opportunities for Bisantrene while protecting its legacy applications.

Commenting on the new strategy, Race Oncology CEO Phillip Lynch said:

The team was excited to share the new Three Pillar strategy at the recent Annual General Meeting. It is the result of a comprehensive review of our core asset, assessing the competitive and commercial environment, and aligning on a goal to actively pursue Bisantrene’s potential as a potent inhibitor of FTO and precision oncology agent. This decision has the potential to unlock significant value for shareholders and the team is progressing the required assessments to ensure we maximise the probability of success.

FTO stands for fat mass and obesity-associated protein. The company continues to investigate Bisantrene’s use as an FTO inhibitor.

The Race Oncology share price has exploded more than 780% higher over the past 12 months.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What sent the Race Oncology (ASX:RAC) share price rocketing 20% today? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!